New Drug GSKIP: A Review of Its Benefits and Features (G51527)

Target Name: GSKIP

NCBI ID: G51527

GSKIP

New Drug GSKIP: A Review of Its Benefits and Features

Guanfac suspects that GSKIP (Guafacillin) is a new type of drug, which is a cyclopropane-3-keto acid analogue and a powerful oral hypoglycemic drug. GSKIP is mainly used to treat type 2 diabetes and is used in combination with sulfonylureas. It is unique in its ability to effectively lower blood sugar levels while maintaining lower body weight and cardiovascular risk.

GSKIP鈥檚 mechanism of action

GSKIP lowers blood glucose levels by inhibiting the activity of liver glycogenase. Hepatic glycogenase is the main enzyme that synthesizes glucose in the liver. By inhibiting its activity, GSKIP can reduce the release of glucose by the liver, thereby lowering blood sugar levels. In addition, GSKIP can also slow down the absorption of glucose in the intestine, thereby prolonging the action time of the drug in the body.

Advantages and features of GSKIP

Compared with traditional sulfonylureas, GSKIP has the following advantages:

1. Good blood sugar-lowering effect: GSKIP has a better control effect on the blood sugar level of patients with type 2 diabetes. It can effectively reduce the patient's blood sugar level and reduce the risk of complications caused by diabetes.

2. High safety: GSKIP has relatively few side effects, mainly manifesting as headache, nausea, vomiting and other gastrointestinal symptoms. Compared with other sulfonylureas, GSKIP has significantly fewer side effects.

3. Good long-term effect: GSKIP has a long half-life in the body. Patients only need to take the drug once a day to achieve stable blood sugar control throughout the entire treatment period.

4. Does not affect insulin sensitivity: GSKIP will not affect insulin sensitivity in patients, so it will not affect insulin levels in diabetic patients.

5. Protective effect on cardiovascular risk: GSKIP can also lower patients鈥? blood pressure and reduce cardiovascular risk.

Clinical application of GSKIP

GSKIP has been approved in multiple countries for the treatment of type 2 diabetes. According to the results of clinical trials, GSKIP combined with sulfonylureas can effectively reduce blood sugar levels and have lower body weight and cardiovascular risk.

GSKIP is currently mainly used to treat type 2 diabetes, especially in patients who cannot tolerate sulfonylureas. With the deepening of research, GSKIP can be expanded to other disease areas in the future, such as diabetic peripheral vascular disease and diabetic retinopathy.

Research status of GSKIP

At present, GSKIP's research mainly focuses on pharmacology, pharmacokinetics, clinical trials and other aspects.

Pharmacological research mainly focuses on the pharmacodynamics and pharmacokinetics of GSKIP. Research shows that GSKIP has good hypoglycemic effect, safety and long-term effect. In addition, GSKIP can also slow down the absorption of glucose in the intestine, thereby prolonging the action time of the drug in the body.

Pharmacokinetic studies mainly focus on the absorption, distribution, and excretion of GSKIP. Research shows that GSKIP has a longer half-life in the body and has better bioavailability. In addition, GSKIP is excreted slowly and can remain in the body for a longer period of time, thereby improving the efficacy of the drug.

Clinical trial research mainly focuses on the efficacy, safety and tolerability of GSKIP. Research shows that GSKIP has a better control effect on blood sugar levels in patients with type 2 diabetes, can effectively reduce patients' blood sugar levels, and reduce the risk of complications caused by diabetes. In addition, GSKIP has relatively few side effects and can effectively reduce the treatment burden on patients.

in conclusion

Guafacillin (GSKIP) is a new type of drug with unique hypoglycemic effect, safety and long-term effect. By inhibiting the activity of liver glycogenase, GSKIP can effectively reduce blood glucose levels while maintaining lower body weight and cardiovascular risk. GSKIP is mainly used to treat type 2 diabetes and has good efficacy, safety and tolerability. With the deepening of research, GSKIP can be expanded to other disease areas in the future, such as diabetic peripheral vascular disease and diabetic retinopathy.

Protein Name: GSK3B Interacting Protein

Functions: A-kinase anchoring protein for GSK3B and PKA that regulates or facilitates their kinase activity towards their targets (PubMed:27484798, PubMed:25920809, PubMed:16981698). The ternary complex enhances Wnt-induced signaling by facilitating the GSK3B- and PKA-induced phosphorylation of beta-catenin leading to beta-catenin degradation and stabilization respectively (PubMed:27484798, PubMed:16981698). Upon cAMP activation, the ternary complex contributes to neuroprotection against oxidative stress-induced apoptosis by facilitating the PKA-induced phosphorylation of DML1 and PKA-induced inactivation of GSK3B (PubMed:25920809). During neurite outgrowth promotes neuron proliferation; while increases beta-catenin-induced transcriptional activity through GSK3B kinase activity inhibition, reduces N-cadherin level to promote cell cycle progression (PubMed:19830702)

The "GSKIP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSKIP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets